000141583 001__ 141583
000141583 005__ 20240321221000.0
000141583 0247_ $$2doi$$a10.5688/ajpe6891
000141583 0247_ $$2pmid$$apmid:31619813
000141583 0247_ $$2pmc$$apmc:PMC6788147
000141583 0247_ $$2ISSN$$a0002-9459
000141583 0247_ $$2ISSN$$a1553-6467
000141583 0247_ $$2altmetric$$aaltmetric:68914528
000141583 037__ $$aDZNE-2020-07907
000141583 041__ $$aEnglish
000141583 082__ $$a610
000141583 1001_ $$aLaw, Ernest H$$b0
000141583 245__ $$aThe Role of Personality in Treatment-Related Outcome Preferences Among Pharmacy Students.
000141583 260__ $$aDes Moines, Iowa$$bAssoc.$$c2019
000141583 264_1 $$2Crossref$$3online$$bAmerican Journal of Pharmaceutical Education$$c2019-09-01
000141583 264_1 $$2Crossref$$3print$$bAmerican Journal of Pharmaceutical Education$$c2019-09-01
000141583 3367_ $$2DRIVER$$aarticle
000141583 3367_ $$2DataCite$$aOutput Types/Journal article
000141583 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1688391106_14565
000141583 3367_ $$2BibTeX$$aARTICLE
000141583 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000141583 3367_ $$00$$2EndNote$$aJournal Article
000141583 520__ $$aObjective. To examine whether personality traits, particularly conscientiousness and agreeableness, were associated with systematic differences in health outcome preferences in cancer treatment scenarios among second-year Doctor of Pharmacy students. Methods. An online survey that quantified outcome preferences using profile best-worst scaling tasks was administered to pharmacy students (n=185). The Big Five personality inventory was used to categorize respondents into tertile-based levels of each trait. Treatment-related health outcomes were described using the EQ-5D-Y system and framed with hypothetical cancer treatment scenarios. Preferences were obtained using count analysis for each treatment-related outcome, and differences based on the level of trait were tested using analysis of variance. Logistic regression was used to test for significant associations between higher levels of a trait and choosing dead over a severe health state. Results. Higher conscientiousness was associated with students who had an approximately 20% more positive preference for 'no problems' in the Usual Activities and Pain/Discomfort attributes, as well as a 19% more negative preference for 'a lot of problems' in the Pain/Discomfort attribute. No differences in treatment preferences were observed across agreeableness tertiles. Higher levels of personality traits were not significantly associated with choosing death over being in moderate health. Conclusion. Conscientiousness appears to be a factor in treatment-related outcome preferences among pharmacy students. Individuals with higher levels of conscientiousness may be more likely to recommend treatments that are less likely to cause pain or discomfort and negatively impact a patient's usual activities.
000141583 536__ $$0G:(DE-HGF)POF3-344$$a344 - Clinical and Health Care Research (POF3-344)$$cPOF3-344$$fPOF III$$x0
000141583 588__ $$aDataset connected to CrossRef, PubMed,
000141583 650_2 $$2MeSH$$aAdult
000141583 650_2 $$2MeSH$$aEducation, Pharmacy
000141583 650_2 $$2MeSH$$aFemale
000141583 650_2 $$2MeSH$$aHumans
000141583 650_2 $$2MeSH$$aMale
000141583 650_2 $$2MeSH$$aNeoplasms: therapy
000141583 650_2 $$2MeSH$$aPatient Preference
000141583 650_2 $$2MeSH$$aPersonality
000141583 650_2 $$2MeSH$$aStudents, Pharmacy: psychology
000141583 650_2 $$2MeSH$$aSurveys and Questionnaires
000141583 650_2 $$2MeSH$$aTreatment Outcome
000141583 650_2 $$2MeSH$$aYoung Adult
000141583 7001_ $$aJiang, Ruixuan$$b1
000141583 7001_ $$0P:(DE-2719)9001134$$aRädke, Anika$$b2$$udzne
000141583 7001_ $$aMühlbacher, Axel$$b3
000141583 7001_ $$aPickard, A Simon$$b4
000141583 77318 $$2Crossref$$3journal-article$$a10.5688/ajpe6891$$b : American Journal of Pharmaceutical Education, 2019-09-01$$n7$$p6891$$tAmerican Journal of Pharmaceutical Education$$v83$$x0002-9459$$y2019
000141583 773__ $$0PERI:(DE-600)2140035-0$$a10.5688/ajpe6891$$gVol. 83, no. 7, p. ajpe6891 -$$n7$$p6891$$q83:7<ajpe6891 -$$tAmerican journal of pharmaceutical education$$v83$$x0002-9459$$y2019
000141583 8567_ $$2Pubmed Central$$uhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC6788147
000141583 909CO $$ooai:pub.dzne.de:141583$$pVDB
000141583 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001134$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000141583 9131_ $$0G:(DE-HGF)POF3-344$$1G:(DE-HGF)POF3-340$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lErkrankungen des Nervensystems$$vClinical and Health Care Research$$x0
000141583 9141_ $$y2019
000141583 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-15
000141583 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-15
000141583 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-15
000141583 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-15
000141583 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-15
000141583 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bAM J PHARM EDUC : 2021$$d2022-11-15
000141583 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-15
000141583 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-15
000141583 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2022-11-15
000141583 9201_ $$0I:(DE-2719)5000001$$kAG Grabe$$lBiomarkers of Dementia in the General Population$$x0
000141583 980__ $$ajournal
000141583 980__ $$aVDB
000141583 980__ $$aI:(DE-2719)5000001
000141583 980__ $$aUNRESTRICTED